Special Issue

Mitochondria and Cancer: From Hidden Culprits to Healing Targets

Message from the Guest Editors

Mitochondria are essential organelles that serve as central regulators of apoptosis, redox homeostasis, cellular metabolism, and innate immune responses -all processes deeply deregulated in cancer. Over the past decade, an expanding body of evidence has elucidated the critical contributions of mitochondrial dysfunction and metabolic reprogramming to tumor initiation, progression, metastasis, and resistance to therapy. We welcome contributions that dissect mitochondrial DNA mutations, metabolic reprogramming, mitochondrial dynamics (fission/fusion), mitophagy, and ROS production and their impact on tumor behavior and immune evasion. Furthermore, preclinical and clinical studies focusing on mitochondria-targeting strategies, including metabolic compounds, pro-apoptotic agents, and mitochondrial transfer, are strongly encouraged. By bringing together basic, translational, and clinical research, this Special Issue aims to provide a comprehensive overview of mitochondrial alterations. highlighting their role both as key drivers of cancer progression and as promising targets for innovative therapeutic intervention.

Guest Editors

Dr. Nicola Amodio

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy

Dr. Marianna Scrima

Laboratory of Molecular and Precision Oncology, Biogem Scarl, Institute of Genetic Research, 83031 Ariano Irpino, Italy

Deadline for manuscript submissions

28 February 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/238458

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

